Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$9K, compared with $206K a year earlier. Trailing-twelve-month accounts receivables was $28K. Over 3 fiscal years it compounded at +23.2% a year.

Context

  • Accounts receivables amounted to 18.7% of revenue in FY2025, down 171.8 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$9K or moves back toward the trailing-twelve-month quarterly average of $7K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9K-101.4% QoQ
Last fiscal yearDec 2025
$243K-36.2% YoY
LTMMar 2026
$28K-97.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-104.4%——
1 year-36.2%——
3-year CAGR+23.2%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
243K USD
Year-over-year change
-36.2%

Accounts Receivables vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.6% is the 5th highest of 6, against a peer median of +207.1%.
  • Accounts receivables amounts to 2.2% of revenue for INBX, versus a peer median of 75.4%.
INBX Competitors
Accounts Receivables for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JANXJanux Therapeutics, Inc.LTM Mar 2026$35M USD+401.4%—161.9%
IMTXImmatics N.V.LTM Mar 2026€1.5M EUR+138.9%-18.5%4.0%
ABSIAbsci CorporationLTM Mar 2026$1.38M USD+207.1%—75.4%
GENBGenerate Biomedicines, Inc.FY2025$308K USD+244.6%—1.0%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$265K USD-134.8%+95.9%236.6%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$28K USD-97.6%+23.2%2.2%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$0 USD———
Peer median (excluding INBX) —+207.1%+38.7%75.4%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(81.77M)(145.23M)(239.73M)1.69B(140.06M)
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
Deferred Income Tax(9K)0000
Stock-Based Compensation15.05M20.45M24.85M58.52M11.14M
Change in Working Capital(17.52M)3.16M15.35M52.05M(7.61M)
Accounts Receivables(167K)130K(521K)381K243K
Inventory(11.03M)0000
Accounts Payables(4.64M)(705K)2.11M17.9M(3.3M)
Other Working Capital(1.67M)3.74M13.76M33.77M(4.56M)
Other Non-Cash Items2.73M5.09M5.03M(1.99B)4.25M
Operating Cash Flow(80.32M)(115.3M)(193.31M)(194.41M)(129.79M)
Capital Expenditures(864K)(686K)(4.59M)(2.6M)(31K)
Acquisitions (Net)55K0003K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(809K)(686K)(4.59M)(2.6M)(28K)
Debt Repayment000099.84M
Common Stock Issued40.2M129.74M201.96M71.68M1.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities83.77M128.81M000
Financing Cash Flow83.77M258.55M201.96M71.68M101.45M
Effect of Forex Changes00000
Net Change in Cash2.64M142.56M4.06M(125.33M)(28.38M)
Free Cash Flow(81.19M)(115.99M)(197.9M)(197.01M)(129.83M)

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.